Retrospective analysis of extra-gastrointestinal stromal tumors
- Retrospective analysis of extra-gastrointestinal stromal tumors
- Gastrointestinal stromal tumor; Survival; Imatinib; Risk factor; Prognostic factor
- Issue Date
- BAISHIDENG PUBLISHING GROUP INC
- WORLD JOURNAL OF GASTROENTEROLOGY, v. 21, NO 6, Page. 1845-1850
- AIM: To investigate the clinicopathologic features of patients with extra-gastrointestinal stromal tumors (EGISTs) in South Korea.
METHODS: A total of 51 patients with an EGIST were identified. The clinicopathologic features, including sex, age, location, tumor size, histology, mitotic rate, immunohistochemical features, genetic status and survival data, were analyzed.
RESULTS: The median age was 55 years (range: 29-80 years), and male: female ratio was 1: 1.04. The most common site was in the mesentery (n = 15) followed by the retroperitoneum (n = 13) and omentum (n = 8). The median tumor size was 9.0 cm (range: 2.6-30.0 cm) and the median mitotic rate was 5.0/50HPF. (1/50 - 185/50). KIT was analyzed in 16, which revealed 10 cases with wild-type KIT and 6 cases with an exon 11 mutation. Among 51 patients, 31 patients had undergone surgery, and 10 had unresectable disease and had taken palliative imatinib, which resulted in 22.7 mo of progression-free survival. Of the patients who had undergone surgery, 18 did not take adjuvant imatinib, and 8 of these were categorized as "high risk" according to the risk criteria. However, the relapse-free survival was not different (P = 0.157) between two groups.
CONCLUSION: Because the biologic behaviors of GISTs differ according to the location of the tumor, a more stratified strategy is required for managing EGISTs including incorporation of molecular features.
- 1007-9327; 2219-2840
- Appears in Collections:
- COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
- Files in This Item:
- Retrospective analysis of extra-gastrointestinal stromal tumors.pdfDownload
- RIS (EndNote)
- XLS (Excel)